Key features and details
- Rabbit polyclonal to IDH1 - N-terminal
- Suitable for: IP
- Reacts with: Human
- Isotype: IgG
Product nameAnti-IDH1 antibody - N-terminal
See all IDH1 primary antibodies
DescriptionRabbit polyclonal to IDH1 - N-terminal
Tested applicationsSuitable for: IPmore details
Species reactivityReacts with: Human
Predicted to work with: Cow, Dog, Pig, Chimpanzee, Orangutan
Synthetic peptide within Human IDH1 aa 1-50 (N terminal). The exact sequence is proprietary. (NP_005887.2).
Database link: O75874
- IP: Jurkat whole cell lysate.
This product was previously labelled as Isocitrate dehydrogenase
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7
Preservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab226190 was affinity purified using an epitope specific to IDH1 immobilized on solid support.
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
Our Abpromise guarantee covers the use of ab226190 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
Involvement in diseaseGlioma
Genetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to Cys, Gly or His abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate.
Sequence similaritiesBelongs to the isocitrate and isopropylmalate dehydrogenases family.
modificationsAcetylation at Lys-374 dramatically reduces catalytic activity.
Cellular localizationCytoplasm. Peroxisome.
- Information by UniProt
- Cytosolic NADP isocitrate dehydrogenase antibody
- Cytosolic NADP-isocitrate dehydrogenase antibody
- Epididymis luminal protein 216 antibody
IDH1 was immunoprecipitated from Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab226190 at 6 µg/mg lysate. Western blot was performed from the immunoprecipitate using a different rabbit anti-IDH1 antibody at 1 µg/ml.
Lane 1: ab226190 IP in Jurkat whole cell lysate.
Lane 2: Control IgG IP in Jurkat whole cell lysate.
Detection: Chemiluminescence with exposure time of 30 seconds.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab226190 has not yet been referenced specifically in any publications.